News | Magnetic Resonance Imaging (MRI) | July 15, 2016

What Free Will Looks Like in the Brain

Johns Hopkins University researchers are the first to glimpse the human brain making a purely voluntary decision to act

MRI, brain activity

An illustration of the human brain indicates where researchers found activity relating to free-will decisions. Image courtesy of Johns Hopkins University.

Unlike most brain studies where scientists watch as people respond to cues or commands, Johns Hopkins researchers found a way to observe people’s brain activity as they made choices entirely on their own. The findings, which pinpoint the parts of the brain involved in decision-making and action, are now online, and due to appear in a special October issue of the journal Attention, Perception, & Psychophysics.

“How do we peek into people’s brains and find out how we make choices entirely on our own?” asked Susan Courtney, a professor of psychological and brain sciences at Johns Hopkins and senior author of the paper. “What parts of the brain are involved in free choice?”

The team devised a novel experiment to track a person’s focus of attention without using intrusive cues or commands. Participants, positioned in MRI scanners, were left alone to watch a split screen as rapid streams of colorful numbers and letters scrolled past on each side. They were asked simply to pay attention to one side for a while, then to the other side — when to switch sides was entirely up to them. Over an hour, the participants switched their attention from one side to the other dozens of times.

Researchers monitored the participants’ brains as they watched the media stream, both before and after they switched their focus.

For the first time, researchers were able to see both what happens in a human brain the moment a free choice is made, and what happens during the lead-up to that decision — how the brain behaves during the deliberation over whether to act.

The actual switching of attention from one side to the other was closely linked to activity in the parietal lobe, near the back of the brain. The activity leading up to the choice — that is, the period of deliberation — occurred in the frontal cortex, in areas involved in reasoning and movement, and in the basal ganglia, regions deep within the brain that are responsible for a variety of motor control functions including the ability to start an action. The frontal-lobe activity began earlier than it would have if participants had been told to shift attention, clearly demonstrating that the brain was preparing a purely voluntary action rather than merely following an order.

Together, the two brain regions make up the core components underlying the will to act, the authors concluded.

“What’s truly remarkable about this project,” said Leon Gmeindl, a research scientist at Johns Hopkins and lead author of the study, “is that by devising a way to detect brain events that are otherwise invisible — that is, a kind of high-tech ‘mind reading’ — we uncovered important information about what may be the neural underpinnings of volition, or free will.”

Now that scientists have a way to track choices made from free will, they can use the technique to determine what’s happening in the brain as people wrestle with other, more complex decisions. For instance, researchers could observe the brain as someone tried to decide between snacking on a doughnut or on an apple — watching as someone weighed short-term rewards against long-term rewards, and perhaps being able to pinpoint the tipping point between the two.

“We now have the ability to learn more about how we make decisions in the real world,” Courtney said.

The research team also included former Johns Hopkins doctoral students and postdoctoral fellows Yu-Chin Chiu, Michael S. Esterman, and Adam S. Greenberg. The paper is dedicated to the last author of the study, Steven Yantis, a professor in the Department of Psychological and Brain Sciences who died of cancer in 2014.

This research was supported by National Institutes of Health grants T32EY07143, T32AG027668, F31-NS055664, R01-MH082957, and R01-DA013165. 

Related Content

Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Siemens Healthineers Demonstrates Artificial Intelligence, Healthcare Digitalization at HIMSS19
News | Artificial Intelligence | February 13, 2019
February 13, 2019 — At the 2019 Healthcare Information and Management Systems Society (HIMSS) global conference and e
Videos | Angiography | February 08, 2019
This is an example of an arterial venous malformation (AVM) in the brain imaged on a...
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Medtronic Recalls Synergy Cranial Software and Stealth Station S7 Cranial Software
News | Procedure Navigation Systems | February 05, 2019
Medtronic is recalling the Synergy Cranial Software and StealthStation S7 Cranial Software used with the StealthStation...
Study Assesses Risk of MRI Exams for Patients With Tattoos
News | Magnetic Resonance Imaging (MRI) | February 01, 2019
A new European study concluded that magnetic resonance imaging (MRI) exams pose little risk for people with tattoos,...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...